How to prepare a deal issues list from transaction documents for Share Purchase Transactions

Prepare a buyer-side deal issues list by reconciling the share purchase agreement, disclosure schedules, ownership records, material contracts, and diligence findings, then translating unresolved concerns into negotiating decisions. Each entry should identify evidence, affected provisions, the buyer’s requested protection, fallback, seller response, and decision-maker. The deliverable is a source-linked negotiating record that distinguishes missing information from established defects and commercial risk acceptance from factual cure. It should tell the deal team what must change, who must decide, and what evidence will close each issue.

When to use this workflow

Use this workflow when buyer’s counsel has a substantive purchase agreement draft and sufficient diligence material to identify contractual protections or client decisions. Prepare or refresh the list before exchanging a markup, holding a negotiation call, or seeking transaction approval.

For a share acquisition, concentrate on the equity being acquired, exposure within the target group, contractual change-of-control triggers, purchase-price mechanics, and seller recourse. This US-oriented guide is a workflow recommendation, not advice for a particular transaction. Delaware corporate-law analysis applies only to relevant Delaware corporations. Rights and remedies depend on the documents, governing law, facts, and negotiated risk allocation; other corporate and regulatory regimes require separate assessment.

What you need

Gather the current share purchase agreement (SPA), prior markup, disclosure schedules, proposed ancillary documents, seller correspondence, and buyer instructions on transaction perimeter and acceptable risk. Include capitalization records, the stock ledger, certificates or uncertificated-share records, equityholder agreements, options, and available issuance and transfer evidence.

Add material contracts and amendments, finance and tax findings, and specialist advice affecting price, conditions, representations, indemnities, or timing. Request missing schedules expressly; an empty folder does not establish inapplicability.

Assign stable document IDs and a review cutoff. Record dates, versions, execution status, and linked amendments. Establish who may approve drafting positions, economic concessions, and significant risk acceptance. Where specialists have not completed review, identify that dependency rather than treating silence as clearance.

Use the template

The Share Purchase Transactions — Deal issues list is a working negotiating record, not a replacement for diligence analysis. Copy this table into your working document or spreadsheet.

Use one row per decision. In “Evidence / gap,” identify document ID, version, clause or page, and uncertainty. “SPA link” covers the affected provision, schedule, or ancillary document; write “not present” when protection is absent.

Explain priority, not just its label. Separate the opening position from an authorized fallback and date seller responses. Identify the responsible person in the live list, not merely a department. The final field should contain status, next action and follow-up date, and the required closure evidence. Link detailed analysis by stable issue ID rather than spreadsheet row number.

Step by step

1. Fix the review baseline and buyer objectives

Identify the negotiated draft, intended sellers, target entities, and whether the buyer expects all shares or a specified interest. Confirm proposed treatment of options, warrants, rollover equity, and excluded interests against available documents.

Identify assumptions underlying approval: retention of a distribution relationship, agreed cash-and-debt treatment, or delivery of specified shares without identified restrictions. Distinguish those assumptions from verified facts. An unresolved discrepancy between the acquisition perimeter and seller coverage needs its own decision.

Record: baseline version, affected objective, supporting documents, and an owner for perimeter uncertainties.

2. Convert diligence findings into discrete decisions

Separate observed facts, missing evidence, and potential consequences. “Consent missing” is premature before establishing whether the relevant contract requires consent for this ownership change. Identify the wording, transaction structure, and unresolved interpretation.

For Delaware corporations, DGCL § 202 addresses permitted transfer restrictions, certificate or notice requirements, actual knowledge, and restrictions adopted after issuance. Missing legends alone do not establish unrestricted transferability. Review the restriction documents and adoption history before recommending approval or waiver. See DGCL § 202(a)–(b). (delcode.delaware.gov)

Record: a neutral issue statement, pinpoint evidence, uncertainty, business exposure, and the analysis or evidence needed next—not an unsupported title conclusion.

3. Connect the concern to the purchase agreement

Map each concern to representations, schedules, covenants, conditions, price adjustments, indemnities, or deliverables. Several provisions may need coordinated changes. A transfer restriction may call for preclosing action and evidence of approval, rather than only a broader title representation.

Read the cross-disclosure clause. In one filed agreement, disclosure against another representation depends on relevance being reasonably apparent on the disclosure’s face. That is negotiated language, not a universal rule. See § 10.9 of the Booz Allen Hamilton–PAR agreement. Test whether the actual SPA gives data-room availability any contractual disclosure effect. (sec.gov)

Record: affected clauses and schedules, missing protection, and the coordinated drafting response.

4. Choose a buyer position and defensible fallback

Match the response to the exposure: obtain information, require corrective action, change economics, allocate risk, or escalate whether to proceed. Explain why the protection works. A representation concerning a missing consent does not obtain that consent.

Check proposed recourse against the actual remedy structure, including applicable limitations, survival, exclusions, and available security. Do not assume an indemnity provides meaningful recovery. Use the buyer’s own negotiation checklist and instructions; mark unapproved fallbacks as internal proposals. State dependencies such as finance validation or approval of residual operating exposure.

Record: requested outcome, fallback, reasoning, approval authority, and conditions for communicating the fallback.

5. Prioritize completion risk separately from risk allocation

Rank effects on ownership, value, operating continuity, recovery, and ability to close. A modest discrepancy may still impede completion if it affects a required seller signature or transfer instrument. Avoid using monetary size as the only severity measure.

Separate regulatory analysis from contractual concessions. FTC guidance describes premerger notification and waiting-period requirements for certain acquisitions, extensions following a Second Request, annually adjusted thresholds, and exemptions. Deal value alone does not determine reportability or a permissible closing date. Refer the question to antitrust counsel using the transaction facts and applicable rules. See the FTC premerger review overview. (ftc.gov)

Record: priority rationale, specialist referral, and unresolved decision dependencies.

6. Reconcile seller responses across the documents

Compare each concession with the revised SPA, schedules, and ancillary documents. Check definitions, qualifiers, remedy limitations, and conflicting provisions. An email saying “accepted” does not establish implementation in the operative draft.

Keep cure separate from contractual acceptance. Section 8.2 of the AMD–ZT Group agreement illustrates buyer closing conditions and specified transfer documents, including a certificate addressing designated conditions. Treat it as drafting evidence, not a universal closing requirement or independent verification of the certified facts. See § 8.2, particularly § 8.2(e). (sec.gov)

Record: dated seller response, revised references, remaining mismatch, and whether closure requires evidence, approval, or both.

7. Produce the decision-ready list

Combine findings seeking the same decision, retaining separate rows when owners or remedies differ. Put transaction-critical open items first and move nonsubstantive drafting cleanup outside the executive discussion.

Verify references against the review baseline and accepted changes against the latest draft. Distinguish “cured,” “contract protection agreed,” and “risk accepted.” If the negotiating issue closes but execution work remains, assign and link that continuing action rather than letting it disappear. Do not turn this list into a complete closing checklist.

Record: status, decision date, supporting approval or document, and the owner and next action for anything continuing.

Worked example

Fictional scenario: Alder Quay Holdings proposes to acquire all shares of Beacon Instruments, Inc., a Delaware corporation, for $46 million. All parties, documents, amounts, and provisions below are fictional. SPA D-01, version 3, is under review. The valuation assumes continuity of a major distribution relationship and consistent treatment of customer deposits.

Holder agreement O-04, version 1, contains an approval restriction, but its adoption history is incomplete. Distribution agreement C-12, executed version, expressly requires written consent for a sale of control; the seller disputes its application without explanation. Workbook F-08, version 2, and the SPA appear to treat deposits inconsistently.

I-01 requires applicability analysis before treating absent approval as a title defect. I-02 changes the agenda from disclosure drafting to operating continuity and the consequences of proceeding without consent. I-03 is only a potential double deduction: the formula and reference working-capital treatment must be tested before quantifying exposure. No missing adoption evidence, consent, or calculation result has been invented. Each entry identifies why stronger representations alone may be insufficient.

Common mistakes

• Listing deficiencies without decisions. Replace “holder agreement missing” with the evidence request, potential transfer consequence, and conditional buyer response.
• Confusing assignment with change of control. Compare the actual trigger with the proposed share acquisition; do not assume both apply.
• Treating disclosure as cure. Assess representation coverage separately from corrective action and residual risk approval.
• Using an indemnity for every concern. Consider consent, price correction, or conditions, and test whether proposed recovery is meaningful.
• Closing on agreement in principle. Verify operative drafting and retain evidence of authorized risk acceptance or factual cure.

Final quality check

• Each entry identifies buyer exposure and a requested decision.
• Document IDs, versions, clauses, pages, and workbook cells resolve correctly.
• Observed facts, missing evidence, and legal conclusions remain distinct.
• Related definitions, schedules, remedies, and ancillary documents have been reconciled.
• Buyer positions and fallbacks have appropriate authority.
• Regulatory questions have a specialist owner and are not treated as seller-waivable concessions.
• Closed entries contain evidence; open entries have an owner, next action, and follow-up date.

Complete the workflow with DecoverAI

DecoverAI is the Legal Intelligence Platform for litigation and transactions. Use contract review with buyer-specific instructions to help identify clause-level concerns; findings quote and locate text, rank severity, and identify missing language. Lawyers control edits as ordinary tracked changes under the signed-in Word user’s name and can dismiss findings with reasons. Due diligence classification and tabular review across documents can support source organization and comparison. The issues list remains the team’s work product, with counsel responsible for verification and judgment. Book a demo to discuss buyer-side issues-list preparation.

Frequently asked questions

Should every diligence finding appear on the issues list?

No. Include findings requiring a negotiating position, client decision, or unresolved completion dependency. Retain supporting detail in the diligence record and link it by issue ID.

Can an issue close before missing evidence arrives?

An authorized decision to accept uncertainty may close negotiation, but it is not factual cure. Record the precise approval and assign any continuing evidence request separately.

How should price-adjustment issues be recorded?

Link definitions to workbook cells and calculation formulas. Identify the disputed treatment, including any reference working-capital effect, and obtain finance validation against a worked calculation before recording agreement.

Should the buyer send its internal list to the seller?

Prepare a separate external version. Keep fallback authority, sensitive commercial reasoning, and internal legal assessments out of the negotiating copy. Communicate the requested outcome and necessary supporting explanation.

Sources

• DGCL § 202 — Delaware transfer-restriction provisions.
• FTC premerger notification overview — notification and waiting-period guidance.
• Booz Allen Hamilton–PAR agreement, § 10.9 — negotiated cross-disclosure example.
• AMD–ZT Group agreement, § 8.2 — negotiated buyer closing conditions.

This guide is general information about legal workflows, not legal advice for any matter. It was drafted and reviewed with AI assistance. The worked example is fictional. Contract rights and procedure depend on the governing law, the actual wording, and the facts, so check the cited sources and the rules that apply in your jurisdiction before relying on it.